Literature DB >> 15583446

The ecarin clotting time, a universal method to quantify direct thrombin inhibitors.

Götz Nowak1.   

Abstract

The ecarin clotting time (ECT) is a meizothrombin generation test that allows for precise quantification of direct thrombin inhibitors. The ECT has demonstrated its usefulness for more than 10 years in biochemical-pharmacological investigations as well as in clinical research and in the clinical routine. It has proved valuable especially as a drug-monitoring method in r-hirudin therapy. This test has been adjusted to clinical requirements by numerous modifications. Following the description of the biochemical background and the measuring principle of the ECT, this article gives a short survey of several modifications of the ECT for both preclinical and clinical use, e.g., for biochemical investigations, as a point-of-care method and for cardiac surgery. Advantages and disadvantages of these methods are discussed. Copyright 2004 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15583446     DOI: 10.1159/000081505

Source DB:  PubMed          Journal:  Pathophysiol Haemost Thromb        ISSN: 1424-8832


  23 in total

1.  Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I study.

Authors:  P Gueret; S Combe; C Krezel; E Fuseau; P L M van Giersbergen; M Petitou; E Neuhart
Journal:  Eur J Clin Pharmacol       Date:  2016-10-15       Impact factor: 2.953

Review 2.  Monitoring target specific anticoagulants.

Authors:  Barbara A Konkle
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

Review 3.  Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations.

Authors:  Helen Mani; Alexander Kasper; Edelgard Lindhoff-Last
Journal:  J Thromb Thrombolysis       Date:  2013-08       Impact factor: 2.300

4.  Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL.

Authors:  Armando Tripodi; Walter Ageno; Marcello Ciaccio; Cristina Legnani; Giuseppe Lippi; Cesare Manotti; Rossella Marcucci; Marco Moia; Benedetto Morelli; Daniela Poli; Agostino Steffan; Sophie Testa
Journal:  Blood Transfus       Date:  2017-09-13       Impact factor: 3.443

Review 5.  Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment.

Authors:  Masaki Watanabe; Fazeel M Siddiqui; Adnan I Qureshi
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

Review 6.  Modifications of natural peptides for nanoparticle and drug design.

Authors:  Andrew P Jallouk; Rohun U Palekar; Hua Pan; Paul H Schlesinger; Samuel A Wickline
Journal:  Adv Protein Chem Struct Biol       Date:  2015-03-12       Impact factor: 3.507

Review 7.  Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents.

Authors:  Abhishek Maan; E Kevin Heist; Jeremy N Ruskin; Moussa Mansour
Journal:  J Atr Fibrillation       Date:  2013-06-30

8.  Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience.

Authors:  Tripti Singh; Thin Thin Maw; Brian L Henry; Núria M Pastor-Soler; Mark L Unruh; Kenneth R Hallows; Thomas D Nolin
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-23       Impact factor: 8.237

9.  A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.

Authors:  Xavier Delavenne; Edouard Ollier; Thierry Basset; Laurent Bertoletti; Sandrine Accassat; Arnauld Garcin; Silvy Laporte; Paul Zufferey; Patrick Mismetti
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

Review 10.  Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.

Authors:  T Steiner; M Böhm; M Dichgans; H-C Diener; C Ell; M Endres; C Epple; M Grond; U Laufs; G Nickenig; H Riess; J Röther; P D Schellinger; M Spannagl; R Veltkamp
Journal:  Clin Res Cardiol       Date:  2013-05-14       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.